Precede Biosciences has announced positive results for its novel liquid biopsy assay, which can classify human epidermal growth factor receptor 2 (HER2) status in multiple cancers and predict ...

Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an ...

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede ...

Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab ...

Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field today There are approximately ...

Rehan Verjee is no stranger to making medicines, having taken several candidates through FDA approvals as the former president of EMD Serono and global head of the Innovative Medicine Franchises at ...

Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers ...